- Home
- CELU vs GSIW Comparison
CELU vs GSIW Comparison
Compare CELU & GSIW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CELU | GSIW |
|---|---|---|
| Founded | 2016 | 2016 |
| Country | United States | Hong Kong |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.3M | 15.1M |
| IPO Year | 2019 | 2022 |
Fundamental Metrics
Financial Performance| Metric | CELU | GSIW |
|---|---|---|
| Price | $1.00 | $9.99 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 114.6K | 8.0K |
| Earning Date | 11-13-2026 | 08-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.04 | N/A |
| Revenue | ★ $26,550,000.00 | N/A |
| Revenue This Year | $165.42 | N/A |
| Revenue Next Year | $305.36 | N/A |
| P/E Ratio | $26.13 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.56 | $0.05 |
| 52 Week High | $2.55 | $38.55 |
Technical Indicators
Market Signals| Indicator | CELU | GSIW |
|---|---|---|
| Relative Strength Index (RSI) | 35.76 | 33.89 |
| Support Level | $0.63 | $9.39 |
| Resistance Level | $1.43 | $12.16 |
| Average True Range (ATR) | 0.14 | 0.75 |
| MACD | -0.06 | 0.20 |
| Stochastic Oscillator | 5.73 | 21.66 |
Price Performance
Historical ComparisonAbout CELU Celularity Inc.
Celularity Inc is a regenerative and cellular medicine company focused on developing placental-derived allogeneic cell therapies and biomaterial products for the treatment of degenerative diseases, aging-related conditions, cancer, and immune disorders. The company operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. It generates the majority of its revenue from the Degenerative Disease segment.
About GSIW Garden Stage Limited
Garden Stage Ltd, through its subsidiaries is a Hong Kong-based financial services provider principally engaged in the provision of placing and underwriting services; securities dealing and brokerage services; asset management services; investment advisory services; due diligence services; and introduction and referral services. The company operates in a single segment and derives all of its revenue from Hong Kong.